Tutor Qualification:Doctoral supervisor

Department:Department of Pharmacology

E-mail：[email protected]

Mailing address:934, West side, 9th Floor, Science and Technology Building, North Campus, Sun Yat-sen University, 74 Zhongshan Second Road, Yuexiu District, Guangzhou

Office Phone:020-87333258

Research direction:Oncolytic Virotherapy (Oncolytic Virotherapy) is an emerging anti-tumor therapy that combines targeted therapy, immunotherapy and gene therapy. Our team focuses on pharmacological research of novel oncolytic viruses, and the research directions mainly include: 1. Molecular mechanism of targeted killing of tumor by oncolytic virus; 2. Study on the double-edged sword regulation mechanism of immune system to oncolytic virus; 3. Apply artificial intelligence and synthetic biology strategies to develop a new generation of oncolytic viruses.

Recipient of the National High - level Youth Talent Program

"Young Pearl River Scholar" of Guangdong Province

"Emerging Scholar" of the Yat - Sen Scholars Program of Sun Yat-sen University

Curriculum Vitae

Since 2024: Professor, Zhongshan School of Medicine, Sun Yat-sen University
2018 - 2024: Associate Professor, Zhongshan School of Medicine, Sun Yat-sen University
2015 - 2018: Post - doctoral Fellow, Sun Yat-sen University
2010 - 2015: Doctor of Philosophy, majoring in Pharmacology, Sun Yat-sen University
2006 - 2010: Bachelor of Science, majoring in Biotechnology, Sun Yat-sen University


Research Interests
Oncolytic Virotherapy is an emerging anti - tumor therapy that combines targeted therapy, immunotherapy and gene therapy. Our team focuses on the pharmacological research of novel oncolytic viruses. The main research directions include:

Research on the molecular mechanisms of oncolytic viruses targeting and killing tumor cells;
Research on the "double - edged sword" regulatory mechanisms of the immune system on oncolytic viruses;
Development of a new generation of oncolytic viruses using artificial intelligence and synthetic biology strategies.

Academic Achievements

Discovered a new oncolytic virus - Alphavirus M1;
Elucidated the molecular mechanisms by which oncolytic virus M1 targets and kills tumor cells;
Oriented - screened a series of enhancers for oncolytic virus M1 based on the molecular mechanisms.
The above basic research has promoted the original new drug oncolytic virus M1 to enter the clinical trial stage in China and Japan.

Academic Publications

  1. Tan, Jingyi#; Zhang, Jiayu#; Hu, Cheng#; Wang Gongwei; Ren, Qianyao; Wang, Chaoqun; Zeng, Zexin; Hu, Jun; Zhu, Wenbo; Liang, Jiankai; Cai, Jing; Yan, Guangmei; Lin, Yuan*. 2024-Pharmacokinetic enhancement of oncolytic virus M1 by inhibiting JAK‒STAT pathway. Acta Pharmaceutica Sinica B. 2024, 14(6):2554e2566.

  2. Guo, Li#; Hu, Cheng#; Liu, Yang; Chen, Xiaoyu; Song, Deli; Shen, Runling; Liu, Zhanzhen; Jia, Xudong; Zhang, Qinfen; Gao, Yuanzhu; Deng, Zhezhi; Zuo, Tao; Hu, Jun; Zhu, Wenbo; Cai, Jing; Yan, Guangmei; Liang Jiankai*; Lin Yuan*. Directed natural evolution generates a next-generation oncolytic virus with a high potency and safety profile.Nature Communications. 2023, 14(1):3410.

  3. Dan, Jia#; Cai, Jing#; Zhong, Yingqian; Wang, Chaoqun; Huang, Shanyu; Zeng, Ying; Fan, Zhen; Xu, Cuiying; Hu, Linyi; Zhang, Jiayu; Hu, Jun; Liu, Ying; Su, Xingwen; Zhu, Wenbo; Yan, Guangmei; Liang, Jiankai*; Lin, Yuan*. Oncolytic virus M1 functions as a bi-functional checkpoint inhibitor to enhance the antitumor activity of DC vaccine. Cell Reports Medicine. 2023, 4(10):101229.

  4. Song, Deli#; Jia, Xudong#; Gao, Yuanzhu#; Xiao, Tong; Dan, Jia; Shen, Runling; Cai, Jing; Liang, Jiankai; Zhu Wenbo; Hu Jun; Yan Guangmei; Zhang Qinfen*; Lin, Yuan *. STT3A-mediated viral N-glycosylation underlies the tumor selectivity of oncolytic virus M1. Oncogene. 2023, 42(48):3575-3588..

  5. Song, Deli#; Jia, Xudong #; Liu, Xincheng #; Hu, Linyi #; Lin, Kaiying; Xiao, Tong; Qiao, Yangyang; Zhang, Jiayu; Dan, Jia; Wong, Chunwa; Hu, Cheng; Sai, Ke; Gong, Shoufang; Sander, Max; Shen, Runling; Chen, Xiaoyu; Xiao, Xiaoting; Chen, Jiehong; Zhang, Yanming; Wei, Cailv; Xiao, Xiao; Liang, Jiankai; Zhang, Qinfen; Hu, Jun; Zhu, Wenbo; Yan, Guangmei; Lin, Yuan*; Cai, Jing*. Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors. Signal Transduction and Targeted Therapy. 2022, 7(1):100.

  6. Liu, Yang#; Xu, Cuiying; Xiao, Xiaoting; Chen, Yinting; Wang, Xiaobo; Liu, Wenfeng; Tan, Yaqian; Zhu, Wenbo; Hu, Jun; Liang, Jiankai; Yan, Guangmei; Lin, Yuan*; Cai, Jing*. Overcoming resistance to oncolytic virus M1 by targeting PI3K-γ in tumor-associated myeloid cells. Molecular Therapy. 2022, 30(12):3677-3693.

  7. Zhu, Wenbo#; Liang, Jiankai; Tan, Jingyi; Guo, Li; Cai, Jing; Hu, Jun; Yan, Guangmei; Liu, Yang; Zhang, Jiayu; Song, Deli; Dan, Jia; Wong, Chun-Wa; Su, Xingwen; Qiu, Pengxin; Lin, Yuan*. Real-Time Visualization and Quantification of Oncolytic M1 Virus In Vitro and In Vivo. Human Gene Therapy. 2021, 32(3-4):158-165.

  8. Zeng, Jiayi; Li, Xiangxue; Sander, Max; Zhang, Haipeng; Yan, Guangmei; Lin, Yuan*. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas. Frontiers in Immunology. 2021, 12: 721830.

  9. Li, Kai#; Hu, Cheng#; Xing, Fan#; Gao, Mingshi; Liang, Jiankai; Xiao, Xiao; Cai, Jing; Tan, Yaqian; Hu, Jun; Zhu, Wenbo; Yin, Wei; Li, Yuan; Chen, Wenli; Lu, Bingzheng; Mai, Jialuo; Qiu, Pengxin; Su, Xingwen; Yan, Guangmei; Zhang, Haipeng*; Lin, Yuan*. Deficiency of the IRE1α-autophagy axis enhances the antitumor effects of the oncolytic virus M1. Journal of Virology, 2018, 92:e01331-17.

  10. Liang, Jiankai#; Guo, Li#; Li, Kai; Xiao, Xiao; Zhu, Wenbo; Zheng, Xiaoke; Hu, Jun; Zhang, Haipeng; Cai, Jing; Yu, Yaya; Tan, Yaqian; Li, Chuntao; Liu, Xincheng; Hu, Cheng; Liu, Ying; Qiu, Pengxin; Su, Xingwen; He, Songmin; Lin, Yuan*; Yan, Guangmei*. Inhibition of the Mevalonate pathway enhances cancer cell oncolysis mediated by M1 Virus. Nature Communications, 2018, 9: 1524.

  11. Xiao, Xiao#; Liang, Jiankai#; Huang, Chunlong; Li, Kai; Xing, Fan; Zhu, Wenbo; Lin, Ziqing; Xu, Wencang; Wu, Guangen; Zhang, Jifu; Lin, Xi; Tan, Yaqian; Cai, Jing; Hu, Jun; Chen, Xueqin; Huang, Youwei; Qin, Zixi; Qiu, Pengxin; Su, Xingwen; Chen, Lijun; Lin, Yuan*; Zhang, Haipeng*; Yan, Guangmei*. DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. Nature Communications, 2018, 9: 4342.

  12. Tan, Yaqian#; Lin, Yuan#; Li, Kai; Xiao, Xiao; Liang, Jiankai; Cai, Jing; Guo, Li; Li, Chuntao; Zhu, Wenbo; Xing, Fan; Mai, Jialuo; Gu, Jiayu; Tan, Xiaohong; Yin, Wei; Lu, Bingzheng; Qiu, Pengxin; Su, Xingwen; Gao, Mingshi; Hu, Jun; He, Songmin; Lu, Ling; Gong, Shoufang; Yan, Guangmei; Zhang, Haipeng*. Selective antagonism of Bcl-xL potentiates M1 oncolysis by enhancing mitochondrial apoptosis. Human Gene Therapy. 2018, 29:950-961.

  13. Zhang, Haipeng#; Li, Kai#; Lin, Yuan#; Xing, Fan; Xiao, Xiao; Cai, Jing; Zhu, Wenbo; Liang, Jiankai; Tan, Yaqian; Fu, Liwu; Wang, Fang; Yin, Wei; Lu, Bingzheng; Qiu, Pengxin; Su, Xingwen; Gong, Shoufang; Bai, Xuetao; Hu, Jun*; Yan, Guangmei*. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Science Translational Medicine. 2017, 9:eaam7996.

  14. Cai, Jing#; Lin, Yuan#; Zhang, Haipeng; Liang, Jiankai; Tan, Yaqian; Cavenee, Webster K.*; Yan, Guangmei*. Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics. Proceedings of the National Academy of Sciences of the United States of America. 2017, 114:6812-6817.

  15. Zhang, Haipeng#; Lin, Yuan#; Li, Kai; Liang, Jiankai; Xiao, Xiao; Cai, Jing; Tan, Yaqian; Xing, Fan; Mai, Jialuo; Li, Yuan; Chen, Wenli; Sheng, Longxiang; Gu, Jiayu; Zhu, Wenbo; Yin, Wei; Qiu, Pengxin; Su, Xingwen; Lu, Bingzheng; Tian, Xuyan; Liu, Jinhui; Lu, Wanjun; Dou, Yunling; Huang, Yijun; Hu, Bing; Kang, Zhuang; Gao, Guangping; Mao, Zixu; Cheng, Shi-Yuan; Lu, Ling; Bai, Xue-Tao; Gong, Shoufang; Yan, Guangmei; Hu, Jun*. Naturally existing oncolytic virus M1 is nonpathogenic for the nonhuman primates after multiple rounds of repeated intravenous injections. Human Gene Therapy. 2016, 27:700-711.

  16. Lin, Yuan#; Zhang, Haipeng#; Liang, Jiankai#; Li, Kai; Zhu, Wenbo; Fu, Liwu; Wang, Fang; Zheng, Xiaoke; Shi, Huijuan; Wu, Sihan; Xiao, Xiao; Chen, Lijun; Tang, Lipeng; Yan, Min; Yang, Xiaoxiao; Tan, Yaqian; Qiu, Pengxin; Huang, Yijun; Yin, Wei; Su, Xinwen; Hu, Haiyan; Hu, Jun*; Yan, Guangmei*. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proceedings of the National Academy of Sciences of the United States of America. 2014, 111:E4504-4512.

  17. Wu, Sihan#; Lin, Yuan#; Xu, Dong; Chen Jingkao; Shu, Minfeng; Zhou, Yuxi; Zhu, Wenbo; Su, Xingwen; Zhou, Yuehan; Qiu, Pengxin; Yan, Gguangmei*. MiR-135a functions as a selective killer of malignant glioma. Oncogene, 2012, 31:3866-3874.

Projects in Charge

National Key R & D Program for Young Scientists (Special Project of Synthetic Biology), December 2021 - November 2026, 5 million yuan;
General Project of the National Natural Science Foundation of China, January 2025 - December 2028, 480,000 yuan;
General Project of the National Natural Science Foundation of China, January 2022 - December 2025, 550,000 yuan;
General Project of the National Natural Science Foundation of China, January 2020 - December 2023, 540,000 yuan;
Youth Science Fund Project of the National Natural Science Foundation of China, January 2017 - December 2019, 190,000 yuan;
General Project of the Natural Science Foundation of Guangdong Province, October 2019 - September 2022, 100,000 yuan;
Doctoral Start-up Project of the Natural Science Foundation of Guangdong Province, June 2016 - June 2019, 100,000 yuan;
General Grant of the China Postdoctoral Science Foundation, January 2016 - December 2018, 80,000 yuan;
Basic Research Operating Expenses for Young Teachers Cultivation Project of Zhongshan University (Central University Basic Research Operating Expenses), January 2019 - December 2021, 200,000 yuan;
Basic Research Operating Expenses for Young Top-notch Scientific Research Talents Cultivation Project of Zhongshan University (Central University Basic Research Operating Expenses), January 2022 - December 2024, 400,000 yuan;
Advanced Medical Technology Research Center Project of Zhongshan School of Medicine - First Affiliated Hospital of Sun Yat-sen University, December 2021 - November 2024, 3 million yuan.
Academic Positions

Young Committee Member of the Teaching and Popular Science Professional Committee of the Chinese Pharmacological Society
Committee Member of the Youth Work Committee of the Guangdong Immunological Society
Committee Member of the Disease Model Branch of the Guangdong Precision Medicine Application Society